Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NervGen Pharma Corp. (NGENF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.2900+0.0500 (+2.23%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2400
Open2.2616
BidN/A x N/A
AskN/A x N/A
Day's Range2.2500 - 2.3300
52 Week Range1.0500 - 2.6700
Volume16,307
Avg. Volume77,433
Market Cap80.605M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-0.2840
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    NervGen Pharma Corp. Closes Non-Brokered Private Placement

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 892,721 units of the Company at a price of .

  • Newsfile

    NervGen Pharma Reports Third Quarter 2021 Results

    Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021."Most notably, we made important progress in our Phase 1 clinical trial with NVG-291 in the third quarter of 2021," stated Paul Bre

  • Newsfile

    NervGen Pharma Completes $9.2 Million Bought Deal Financing

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment o

Advertisement
Advertisement